Concepedia

Complement Therapeutic Safety

Complement Therapeutic Safety is a scholarly construct within complement-targeted therapy that denotes the systematic assessment and mitigation of adverse effects associated with therapeutic modulation of the complement system, distinguishing it from related efficacy-focused or mechanistic approaches by prioritizing the identification, evaluation, and management of treatment-induced immunological risks.

19

Publications

1.6K

Citations

248

Authors

156

Institutions

Publications per year

2017–2026

13

Parents

Publications

19

Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

Peter Hillmen, Petra Muus, Alexander Röth et al. · British Journal of Haematology · 2013 · 387 citations · Full text

, , +17

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine

Lucy A. McNamara, Nadav Topaz, Xin Wang et al. · MMWR Morbidity and Mortality Weekly Report · 2017 · 335 citations · Full text

, , +16

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini et al. · Blood · 2022 · 115 citations · Full text

, , +17

An open label clinical trial of complement inhibition in multifocal motor neuropathy

Amanda Fitzpatrick, Cameron Mann, Sarah Barry et al. · Journal of the Peripheral Nervous System · 2011 · 103 citations

, , +17

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine

Lucy A. McNamara, Nadav Topaz, Xin Wang et al. · American Journal of Transplantation · 2017 · 103 citations · Full text

, , +16

1–5 of 19

Authors

248

  1. AM
    Antonio M. Risitano

    University of Naples Federico II, Italy

    3 publications · 465 citations

    3

    h-index

  2. MS
    Michael Storek

    Sanofi (United States), United States

    3 publications · 160 citations

    3

    h-index

  3. AR
    Alexander Röth

    University of Duisburg-Essen, Germany

    3 publications · 523 citations

    3

    h-index

  4. WB
    Wilma Barcellini

    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy

    3 publications · 181 citations

    3

    h-index

  5. ME
    Modupe Elebute

    Alexion Pharmaceuticals (United States), United States

    2 publications · 411 citations

    2

    h-index

1–5 of 248

Institutions

156

  1. Alexion Pharmaceuticals (United States)

    Boston, United States

    5 h-index

    23 publications

    915 citations

  2. Sanquin

    Amsterdam, Netherlands

    3 h-index

    3 publications

    181 citations

  3. University of Duisburg-Essen

    Essen, Germany

    3 h-index

    3 publications

    523 citations

  4. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

    3 h-index

    3 publications

    181 citations

  5. The University of Osaka

    Osaka, Japan

    3 h-index

    4 publications

    304 citations

  6. King's College Hospital

    London, United Kingdom

    3 h-index

    3 publications

    456 citations

  7. University College London Hospitals NHS Foundation Trust

    London, United Kingdom

    2 h-index

    2 publications

    136 citations

  8. University of Southern California

    Los Angeles, United States

    2 h-index

    4 publications

    187 citations

1–8 of 156

Venues

  1. Blood

    4 publications · 177 citations

    4

    h-index

  2. American Journal of Hematology

    AJH · 2 publications · 83 citations

    2

    h-index

  3. American Journal of Reproductive Immunology

    AJRI · 1 publications · 11 citations

    1

    h-index

  4. Kidney International

    1 publications · 90 citations

    1

    h-index

  5. Investigative Ophthalmology & Visual Science

    IOVS · 1 publications · 14 citations

    1

    h-index

1–5